KR20220166578A - Anti-aging composition comprising 4-hexylresorcinol as an active ingredient - Google Patents
Anti-aging composition comprising 4-hexylresorcinol as an active ingredient Download PDFInfo
- Publication number
- KR20220166578A KR20220166578A KR1020210075500A KR20210075500A KR20220166578A KR 20220166578 A KR20220166578 A KR 20220166578A KR 1020210075500 A KR1020210075500 A KR 1020210075500A KR 20210075500 A KR20210075500 A KR 20210075500A KR 20220166578 A KR20220166578 A KR 20220166578A
- Authority
- KR
- South Korea
- Prior art keywords
- aging
- hexylresorcinol
- present
- composition
- active ingredient
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 36
- 229960003258 hexylresorcinol Drugs 0.000 title claims abstract description 28
- 239000004101 4-Hexylresorcinol Substances 0.000 title claims abstract description 27
- WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 235000019360 4-hexylresorcinol Nutrition 0.000 title claims abstract description 27
- 230000003712 anti-aging effect Effects 0.000 title claims abstract description 26
- 239000004480 active ingredient Substances 0.000 title claims abstract description 15
- 101150109526 Sirt6 gene Proteins 0.000 claims abstract description 19
- 230000014509 gene expression Effects 0.000 claims abstract description 19
- 201000010099 disease Diseases 0.000 claims description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 230000032683 aging Effects 0.000 claims description 16
- 230000036541 health Effects 0.000 claims description 10
- 101000616738 Homo sapiens NAD-dependent protein deacetylase sirtuin-6 Proteins 0.000 claims description 8
- 102100021840 NAD-dependent protein deacetylase sirtuin-6 Human genes 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 206010063493 Premature ageing Diseases 0.000 claims description 5
- 208000032038 Premature aging Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 230000007812 deficiency Effects 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 abstract description 8
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract description 4
- 108090000623 proteins and genes Proteins 0.000 description 11
- 108010041191 Sirtuin 1 Proteins 0.000 description 10
- 102000000344 Sirtuin 1 Human genes 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000013305 food Nutrition 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000011990 Sirtuin Human genes 0.000 description 3
- 108050002485 Sirtuin Proteins 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 229940014259 gelatin Drugs 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007902 hard capsule Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- -1 patches Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102000000477 Sirtuin 2 Human genes 0.000 description 2
- 108010041216 Sirtuin 2 Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 101150089009 sir2 gene Proteins 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 238000013382 DNA quantification Methods 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101000654472 Homo sapiens NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 1
- JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical group NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 101150051587 SIRT7 gene Proteins 0.000 description 1
- 101150074067 Sirt4 gene Proteins 0.000 description 1
- 102000000478 Sirtuin 3 Human genes 0.000 description 1
- 108010041218 Sirtuin 3 Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000010094 cellular senescence Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000056482 human SIRT1 Human genes 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000011076 safety test Methods 0.000 description 1
- 101150045247 sirt5 gene Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
본 발명은 4-헥실레조르시놀(4-hexylresorcinol)을 유효성분으로 포함하는 항노화용 조성물에 관한 것이다.The present invention relates to an anti-aging composition comprising 4-hexylresorcinol as an active ingredient.
노화는 시간이 흐름에 따라 생물의 신체기능이 퇴화하는 현상이다. 세포의 노화는 세포가 분열할 수 있는 능력을 잃어버리는 것으로 나타난다. 줄기세포 역시 세포군이기 때문에 점차 그 기능을 서서히 소실하게 된다. 일반적으로 세포의 노화는 Rb(retinoblastoma) 단백질에 의존적인 노화기전과 염색체를 보호하는 역할을 담당하는 텔로미어(telomere)의 손실로 일어나는 노화, 항산화 스트레스에 의한 노화, DNA 손상에 의한 노화 등이 있다. 이러한 DNA 손상신호 전달기전과 스트레스 신호전달 기전이 외부 환경적 요인에 의해 발생할 수 있는 세포의 변형을 억제하는 종양억제 신호전달과 많은 부분을 공유하며 많은 관련 유전자들에 대한 연구가 진행되고 있다.Aging is a phenomenon in which the bodily functions of organisms deteriorate over time. Cellular senescence is manifested by the loss of the ability of cells to divide. Since stem cells are also a group of cells, they gradually lose their function. In general, cellular aging includes an aging mechanism dependent on Rb (retinoblastoma) protein, aging caused by loss of telomeres responsible for protecting chromosomes, aging due to antioxidant stress, and aging due to DNA damage. The DNA damage signal transduction mechanism and the stress signal transduction mechanism share many parts with the tumor suppressor signal transduction that inhibits cell transformation that may occur due to external environmental factors, and many related genes are being studied.
다양한 노화 관련 인자들중에서 Deacetylation 효소 활성을 갖는 Sirtuin family. Sirtuin family는 포유동물에서 Sirt1, Sirt2, Sirt3, Sirt4, Sirt5, Sirt6와 Sirt7로 이루어져 있으며, 수명연장 조절단백질로 간주되어 왔다.Among various aging-related factors, the Sirtuin family with deacetylation enzyme activity. The Sirtuin family consists of Sirt1, Sirt2, Sirt3, Sirt4, Sirt5, Sirt6 and Sirt7 in mammals, and has been considered as a lifespan extension regulatory protein.
서투인1(Sirtuin1; SIRT1)은 만성염증, 암, 노화를 조절하는 유전자에 속하며, SIR2라는 이스트의 유전자가 에너지 처리과정을 조절하는 마스터 스위치 역할을 하는 것이라고 보고된 바 있다. SIR2 유전자가 활성화된 세포는 평균수명보다 오래 사는 반면, SIR2 유전자가 결여된 세포는 수명이 짧음이 증명되었다. 그 후 꼬마선충, 초파리의 경우 SIR2가 과잉발현되면 수명이 연장되는 것으로 밝혀졌으며, 포유류의 SIRT1 유전자가 SIR2와 등가이며, 동일한 작용을 한다는 연구결과가 발표된 바 있다. 인간의 SIRT1은 히스톤과 비히스톤 단백질을 탈아세틸화하여 염증매개물질을 조절하는 NAD+ 의존성 단백질/히스톤 탈아세틸화효소로써, 항노화ㆍ항염 단백질로 알려져 있다. 최근에는 SIRT1이 스트레스, 대사, 세포사멸, 조로 등에 긍정적 역할을 미친다는 연구결과들이 발표되고 있다.Sirtuin1 (SIRT1) belongs to genes that regulate chronic inflammation, cancer, and aging, and it has been reported that a yeast gene called SIR2 acts as a master switch to regulate energy processing. Cells with an activated SIR2 gene live longer than average, while cells lacking the SIR2 gene have a shorter lifespan. Subsequently, in the case of Caenorhabditis elegans and Drosophila, it was found that overexpression of SIR2 extends lifespan, and research results have been published that the mammalian SIRT1 gene is equivalent to SIR2 and has the same effect. Human SIRT1 is a NAD+ dependent protein/histone deacetylase that regulates inflammatory mediators by deacetylating histone and non-histone proteins, and is known as an anti-aging and anti-inflammatory protein. Recently, studies have been published showing that SIRT1 plays a positive role in stress, metabolism, apoptosis, and premature aging.
Sirtuin family 중에서도 Sirt1은 효모 Sir2 단백질과 가장 유사한 아미노산 배열을 갖고 있어서, 연구결과에 따르면 Sirt1 KO 마우스는 Embryonic lethal 하며, 조직 특이적으로 Sirt1을 결실 시 Sirt1이 노인성 질환과 (퇴행성신경질환, 당뇨, 암, 등) 과 밀접한 연관성이 있음을 보여주었으며, Sirt1를 과발현 하면 노인성 질환이 감소됨을 확인되었다. Sirt2, 3, 4, 5, 및 7 각각의 KO 마우스는 암발생 증가, Hearing loss, 심장질환 등 다양한 노인성 관련 질환 표현형들이 관찰되었으며, Sirt6 KO 마우스는 조로증(Premature aging)과 유사한 표현형을 보여주었고, Sirt6 과발현 transgenic 마우스는 수명이 약 15-20% 증가한다는 연구 결과가 발표되었다.Among the Sirtuin family, Sirt1 has the most similar amino acid sequence to the yeast Sir2 protein. According to research results, Sirt1 KO mice are Embryonic lethal, and when tissue-specific deletion of Sirt1 occurs, Sirt1 is associated with senile diseases (degenerative neurological diseases, diabetes, cancer). , etc.), and overexpression of Sirt1 reduced senile diseases. Each of the Sirt2, 3, 4, 5, and 7 KO mice showed various senile-related disease phenotypes such as increased cancer incidence, hearing loss, and heart disease, and Sirt6 KO mice showed a phenotype similar to premature aging, Studies have shown that the lifespan of transgenic mice overexpressing Sirt6 increases by about 15-20%.
본 발명은 항노화용 조성물을 제공하기위해, 4-헥실레조르시놀(4-hexylresorcinol)이 혈관내피세포에서 항노화와 관련된 Sirt6 유전자의 발현을 촉진시키는 것을 확인함으로써, 4-헥실레조르시놀(4-hexylresorcinol)을 항노화 제제로 제공하는 것이다.In order to provide an anti-aging composition, the present invention confirms that 4-hexylresorcinol promotes the expression of the Sirt6 gene related to anti-aging in vascular endothelial cells. -hexylresorcinol) as an anti-aging agent.
본 발명은 4-헥실레조르시놀(4-hexylresorcinol)을 유효성분으로 포함하는 항노화용 조성물을 제공한다.The present invention provides an anti-aging composition comprising 4-hexylresorcinol as an active ingredient.
또한, 본 발명은 상기 항노화용 조성물을 유효성분으로 포함하는 노화 질환의 예방 또는 치료용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating aging diseases comprising the anti-aging composition as an active ingredient.
또한, 본 발명은 상기 항노화용 조성물을 유효성분으로 포함하는 노화 질환의 예방 또는 개선용 건강기능 식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving aging diseases comprising the anti-aging composition as an active ingredient.
또한, 본 발명은 4-헥실레조르시놀(4-hexylresorcinol)을 유효성분으로 포함하는 Sirt6의 발현 촉진을 위한 시약 조성물을 제공한다.In addition, the present invention provides a reagent composition for promoting the expression of Sirt6 comprising 4-hexylresorcinol as an active ingredient.
본 발명에 따르면, 4-헥실레조르시놀(4-hexylresorcinol)이 혈관내피세포에서 항노화와 관련된 Sirt6 유전자의 발현을 촉진시키는 것을 확인함으로써, 4-헥실레조르시놀(4-hexylresorcinol)을 항노화 제제로 제공될 수 있다.According to the present invention, by confirming that 4-hexylresorcinol promotes the expression of the Sirt6 gene related to anti-aging in vascular endothelial cells, 4-hexylresorcinol is anti-aging. It may be provided as a formulation.
도 1은 4-헥실레조르시놀(4-hexylresorcinol)이 Sirt6의 발현을 유도하여 항노화 기작을 나타내는 모식도이다.
도 2는 4-헥실레조르시놀(4-hexylresorcinol)이 Sirt6 유전자의 발현에 미치는 영향을 평가한 결과이다.
도 3은 4-헥실레조르시놀(4-hexylresorcinol)이 Sirtuin 6 단백질 발현에 미치는 영향을 평가한 결과이다.1 is a schematic diagram showing an anti-aging mechanism by inducing the expression of Sirt6 by 4-hexylresorcinol.
Figure 2 shows the results of evaluating the effect of 4-hexylresorcinol on the expression of the Sirt6 gene.
3 is a result of evaluating the effect of 4-hexylresorcinol on Sirtuin 6 protein expression.
본 명세서에서 사용되는 용어는 본 발명에서의 기능을 고려하면서 가능한 현재 널리 사용되는 일반적인 용어들을 선택하였으나, 이는 당 분야에 종사하는 기술자의 의도 또는 판례, 새로운 기술의 출현 등에 따라 달라질 수 있다. 또한, 특정한 경우는 출원인이 임의로 선정한 용어도 있으며, 이 경우 해당되는 발명의 설명 부분에서 상세히 그 의미를 기재할 것이다. 따라서 본 발명에서 사용되는 용어는 단순한 용어의 명칭이 아닌, 그 용어가 가지는 의미와 본 발명의 전반에 걸친 내용을 토대로 정의되어야 한다.The terms used in this specification have been selected from general terms that are currently widely used as much as possible while considering the functions in the present invention, but these may vary depending on the intention of a person skilled in the art, precedent, or the emergence of new technologies. In addition, in a specific case, there is also a term arbitrarily selected by the applicant, and in this case, the meaning will be described in detail in the description of the invention. Therefore, the term used in the present invention should be defined based on the meaning of the term and the overall content of the present invention, not simply the name of the term.
다르게 정의되지 않는 한, 기술적이거나 과학적인 용어를 포함해서 여기서 사용되는 모든 용어들은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에 의해 일반적으로 이해되는 것과 동일한 의미를 가지고 있다. 일반적으로 사용되는 사전에 정의되어 있는 것과 같은 용어들은 관련 기술의 문맥상 가지는 의미와 일치하는 의미를 가지는 것으로 해석되어야 하며, 본 출원에서 명백하게 정의하지 않는 한, 이상적이거나 과도하게 형식적인 의미로 해석되지 않는다.Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related art, and unless explicitly defined in this application, it should not be interpreted in an ideal or excessively formal meaning. don't
수치 범위는 상기 범위에 정의된 수치를 포함한다. 본 명세서에 걸쳐 주어진 모든 최대의 수치 제한은 낮은 수치 제한이 명확히 쓰여 있는 것처럼 모든 더 낮은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 최소의 수치 제한은 더 높은 수치 제한이 명확히 쓰여 있는 것처럼 모든 더 높은 수치 제한을 포함한다. 본 명세서에 걸쳐 주어진 모든 수치 제한은 더 좁은 수치 제한이 명확히 쓰여 있는 것처럼, 더 넓은 수치 범위 내의 더 좋은 모든 수치 범위를 포함할 것이다.Numerical ranges are inclusive of the values defined therein. Every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitations were expressly written. Every minimum numerical limitation given throughout this specification includes every higher numerical limitation, as if such higher numerical limitations were expressly written. Every numerical limitation given throughout this specification will include every better numerical range within the broader numerical range, as if the narrower numerical limitations were expressly written.
이하, 본 발명을 보다 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.
본 발명은 4-헥실레조르시놀(4-hexylresorcinol)을 유효성분으로 포함하는 항노화용 조성물을 제공한다.The present invention provides an anti-aging composition comprising 4-hexylresorcinol as an active ingredient.
상기 4-헥실레조르시놀(4-hexylresorcinol)은 Sirt6의 발현을 촉진한다. 상기 Sirt6 유전자는 동물 모델에서 녹아웃시 조로증(Premature aging)의 증상이 나타나고, 과발현시 수명이 약 15-20% 증가하는 것으로 보고되었으며, 항노화와 수면연장에 관련이 있는 유전자로 보고되었다.The 4-hexylresorcinol promotes the expression of Sirt6. The Sirt6 gene has been reported to show symptoms of premature aging when knocked out in animal models, and to increase lifespan by about 15-20% when overexpressed, and has been reported as a gene related to anti-aging and sleep prolongation.
또한, 본 발명은 상기 항노화용 조성물을 유효성분으로 포함하는 노화 질환의 예방 또는 치료용 약학적 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating aging diseases comprising the anti-aging composition as an active ingredient.
상기 노화 질환은 시르투인 6(Sirtuin 6)의 결핍으로 발병되는 질환이고, 구체적으로 암, 지방간, 심근비대증, 조기 노화, 당뇨병, 알츠하이머병, 및 염증성 질환으로 이루어진 군에서 선택된 어느 하나일 수 있다.The aging disease is a disease caused by a deficiency of Sirtuin 6, and specifically, may be any one selected from the group consisting of cancer, fatty liver, myocardial hypertrophy, premature aging, diabetes, Alzheimer's disease, and inflammatory diseases. .
상기 약학적 조성물은 시르투인 6(Sirtuin 6)의 수준이 낮은 환자를 대상으로 하며, 시르투인 6(Sirtuin 6)의 수준이 낮은 환자로부터 시르투인 6(Sirtuin 6)의 결핍으로 발병되는 질환을 개선시키기 위해 투여될 수 있다.The pharmaceutical composition is intended for patients with low levels of Sirtuin 6, and patients with low levels of Sirtuin 6 develop from deficiency of Sirtuin 6. It can be administered to ameliorate the disease.
본 발명의 약학적 조성물은 당해 발명이 속하는 기술분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다.The pharmaceutical composition of the present invention is prepared in unit dosage form or multi-dose by formulating using a pharmaceutically acceptable carrier according to a method that can be easily performed by those skilled in the art. It can be prepared by incorporating into a container.
상기 약제학적으로 허용되는 담체는 제제시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸 히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다.The pharmaceutically acceptable carrier is one commonly used in formulation, and includes lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. The pharmaceutical composition of the present invention may further include a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like in addition to the above components.
본 발명에 있어서, 상기 약학적 조성물에 포함되는 첨가제의 함량은 특별히 한정되는 것은 아니며 통상의 제제화에 사용되는 함량 범위 내에서 적절하게 조절될 수 있다.In the present invention, the content of the additives included in the pharmaceutical composition is not particularly limited and may be appropriately adjusted within the range of content used in conventional formulations.
상기 약학적 조성물은 수용액, 현탁액, 유탁액 등과 같은 주사용 제형, 환약, 캡슐, 과립, 정제, 크림, 젤, 패취, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 및 카타플라스마제로 이루어진 군으로부터 선택되는 하나 이상의 외용제 형태로 제형화될 수 있다.The pharmaceutical composition may be formulated as an aqueous solution, suspension, emulsion, etc. for injection, pills, capsules, granules, tablets, creams, gels, patches, sprays, ointments, warning agents, lotions, liniment agents, pasta agents, and cataplasma agents. It may be formulated in the form of one or more external preparations selected from the group consisting of agents.
본 발명의 약학적 조성물은 제형화를 위해 추가로 있는 약학적으로 허용가능한 담체 및 희석제를 포함할 수 있다. 상기 약학적으로 허용가능한 담체 및 희석제는 전분, 당, 및 만니톨과 같은 부형제, 칼슘 포스페이트 등과 같은 충전제 및 증량제, 카르복시메틸셀룰로오스, 히드록시프로필셀룰로오스 등과 같은 셀룰로오스 유도체, 젤라틴, 알긴산염, 및 폴리비닐 피롤리돈 등과 같은 결합제, 활석, 스테아린산 칼슘, 수소화 피마자유 및 폴리에틸렌 글리콜과 같은 윤활제, 포비돈, 크로스포비돈과 같은 붕해제, 폴리소르베이트, 세틸알코올, 및 글리세롤 등과 같은 계면활성제를 포함하나, 이에 한정되지 않는다. 상기 약학적으로 허용가능한 담체 및 희석제는 대상체에게 생물학적 및 생리학적으로 친화적인 것일 수 있다. 희석제의 예로는 염수, 수용성 완충액, 용매 및/또는 분산제(dispersion media)를 들 수 있으나, 이에 제한되는 것은 아니다.The pharmaceutical composition of the present invention may further contain pharmaceutically acceptable carriers and diluents for formulation. The pharmaceutically acceptable carriers and diluents include excipients such as starch, sugar and mannitol, fillers and extenders such as calcium phosphate, cellulose derivatives such as carboxymethylcellulose and hydroxypropylcellulose, gelatin, alginates, and polyvinyl fibres. binders such as rolidone, etc., lubricants such as talc, calcium stearate, hydrogenated castor oil and polyethylene glycol, disintegrants such as povidone, crospovidone, surfactants such as polysorbates, cetyl alcohol, and glycerol; don't The pharmaceutically acceptable carrier and diluent may be biologically and physiologically compatible with the subject. Examples of diluents include, but are not limited to, saline, aqueous buffers, solvents and/or dispersion media.
본 발명의 약학적 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구 투여(예를 들어, 정맥 내, 피하, 복강 내 또는 국소에 적용)할 수 있다. 경구 투여일 경우, 정제, 트로키제 (troches), 로젠지 (lozenge), 수용성 현탁액, 유성 현탁액, 조제 분말, 과립, 에멀젼, 하드 캡슐, 소프트 캡슐, 시럽 또는 엘릭시르제 등으로 제형화될 수 있다. 비경구 투여일 경우, 주사액, 좌제, 호흡기 흡입용 분말, 스프레이용 에어로졸제, 연고, 도포용 파우더, 오일, 크림 등으로 제형화 될 수 있다.The pharmaceutical composition of the present invention may be administered orally or parenterally (eg, intravenous, subcutaneous, intraperitoneal or topical application) depending on the desired method. For oral administration, it may be formulated into tablets, troches, lozenges, aqueous suspensions, oily suspensions, powders, granules, emulsions, hard capsules, soft capsules, syrups or elixirs. In the case of parenteral administration, it may be formulated as an injection solution, suppository, powder for respiratory inhalation, aerosol for spray, ointment, powder for application, oil, cream, etc.
본 발명의 약학적 조성물의 투여량은 환자의 상태 및 체중, 연령, 성별, 건강상태, 식이 체질 특이성, 제제의 성질, 질병의 정도, 조성물의 투여시간, 투여방법, 투여기간 또는 간격, 배설율, 및 약물 형태에 따라 그 범위가 다양할 수 있으며, 이 분야 통상의 기술자에 의해 적절하게 선택될 수 있다. 예컨대, 약 0.1 내지 10,000 mg/kg의 범위일 수 있으나 이제 제한되지 않으며, 하루 일회 내지 수회에 나누어 투여될 수 있다.The dosage of the pharmaceutical composition of the present invention depends on the condition and weight of the patient, age, sex, health condition, dietary constitution specificity, the nature of the preparation, the severity of the disease, the administration time of the composition, the administration method, the administration period or interval, and the excretion rate. , And the range may vary depending on the type of drug, and may be appropriately selected by a person skilled in the art. For example, it may be in the range of about 0.1 to 10,000 mg/kg, but is not limited thereto, and may be divided and administered once or several times a day.
상기 약학적 조성물은 목적하는 방법에 따라 경구 투여되거나 비경구 투여(예를 들면, 정맥 내, 피하 내, 복강 내 또는 국소에 적용)될 수 있다. 본 발명의 약학적 조성물의 약학적 유효량, 유효 투여량은 약학적 조성물의 제제화 방법, 투여 방식, 투여 시간 및/또는 투여 경로 등에 의해 다양해질 수 있으며, 당해 기술 분야에서 통상의 지식을 가진 자는 목적하는 치료에 효과적인 투여량을 용이하게 결정하고 처방할 수 있다. 본 발명의 약학적 조성물의 투여는 하루에 1회 투여될 수 있고, 수회에 나누어 투여될 수도 있다.The pharmaceutical composition may be administered orally or parenterally (eg, intravenous, subcutaneous, intraperitoneal or topical application) depending on the desired method. The pharmaceutically effective amount and effective dose of the pharmaceutical composition of the present invention may vary depending on the formulation method, administration method, administration time and/or administration route of the pharmaceutical composition, and those skilled in the art can use the purpose Dosages effective for treatment can be easily determined and prescribed. Administration of the pharmaceutical composition of the present invention may be administered once a day, or may be divided into several administrations.
또한, 본 발명은 상기 항노화용 조성물을 유효성분으로 포함하는 노화 질환의 예방 또는 개선용 건강기능 식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving aging diseases comprising the anti-aging composition as an active ingredient.
본 발명은 통상적으로 이용되는 식품으로써 일반적으로 사용될 수 있다.The present invention can be generally used as a commonly used food.
본 발명의 식품 조성물은 건강기능식품으로서 사용될 수 있다. 상기 "건강기능 식품"이라 함은 건강기능 식품에 관한 법률에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, "기능성"이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻을 목적으로 섭취하는 것을 의미한다.The food composition of the present invention can be used as a health functional food. The term "health functional food" refers to food manufactured and processed using raw materials or ingredients having useful functionalities for the human body in accordance with the Health Functional Food Act, and "functional" refers to food that is not related to the structure and function of the human body. It refers to intake for the purpose of obtaining useful effects for health purposes such as regulating nutrients or physiological functions.
본 발명의 식품 조성물은 통상의 식품 첨가물을 포함할 수 있으며, 상기 "식품 첨가물"로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전처에 승인된 식품 첨가물 공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.The food composition of the present invention may include conventional food additives, and the suitability as the "food additive" is determined according to the general rules of the food additive code approved by the Ministry of Food and Drug Safety and general test methods, etc., unless otherwise specified. It is judged according to the specifications and standards for the item.
상기 "식품 첨가물 공전"에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼륨, 니코틴산, 계피산 등의 화학적 합성물, 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료제제, 타르색소제제 등의 혼합제제류들을 들 수 있다.Items listed in the "Food Additive Code" include, for example, chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as dark pigment, licorice extract, crystalline cellulose, goyang pigment, guar gum, and mixed preparations such as sodium L-glutamate preparations, noodle-added alkali preparations, preservative preparations, and tar color preparations.
본 발명의 식품 조성물은 정제, 캡슐, 분말, 과립, 액상, 환 등의 형태로 제조 및 가공할 수 있다.The food composition of the present invention can be prepared and processed in the form of tablets, capsules, powders, granules, liquids, pills and the like.
예를 들어, 캡슐 형태의 건강기능 식품 중 경질캡슐제는 통상의 경질캡슐에 본 발명에 따른 조성물을 부형제 등의 첨가제와 혼합 및 충진하여 제조할 수 있으며, 연질캡슐제는 본 발명에 따른 조성물의 부형제 등의 첨가제와 혼합하고 젤라틴 등 캡슐기제에 충진하여 제조할 수 있다. 상기 연질캡슐제는 필요에 따라 글리세린 또는 소르비톨 등의 가소제, 착색제, 보존제 등을 함유할 수 있다.For example, among the health functional foods in the form of capsules, hard capsules can be prepared by mixing and filling the composition according to the present invention with additives such as excipients in conventional hard capsules, and soft capsules can be prepared by filling the composition according to the present invention. It can be prepared by mixing with additives such as excipients and filling in a capsule base such as gelatin. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a colorant, a preservative, and the like, if necessary.
상기 부형제, 결합제, 붕해제, 활택제, 교미제, 착향제 등에 대한 용어 정의는 당업계에 공지된 문헌에 기재된 것으로 그 기능 등이 동일 내지 유사한 것들을 포함한다. 상기 식품의 종류에는 특별한 제한이 없으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다.Definitions of terms for the excipients, binders, disintegrants, lubricants, corrigents, flavoring agents, etc. are described in literature known in the art, and include those having the same or similar functions. There is no particular limitation on the type of food, and it includes all health functional foods in the usual sense.
본 발명에서 용어 “예방”이란 본 발명에 따른 조성물의 투여로 질환의 억제 또는 지연시키는 모든 행위를 말한다. 본 발명에서 용어 “치료”는 본 발명에 따른 조성물의 투여로 질환의 증세가 호전되거나 이롭게 변경하는 모든 행위를 말한다. 본 발명에서 "개선"이란 본 발명의 조성물을 개체에 투여하거나 섭취시켜 질환의 나쁜 상태를 좋게 하는 모든 행위를 의미한다.In the present invention, the term "prevention" refers to all activities that inhibit or delay a disease by administering the composition according to the present invention. In the present invention, the term "treatment" refers to all activities that improve or beneficially change the symptoms of a disease by administering the composition according to the present invention. In the present invention, "improvement" means any action that improves the bad condition of a disease by administering or ingesting the composition of the present invention to a subject.
또한, 본 발명은 4-헥실레조르시놀(4-hexylresorcinol)을 유효성분으로 포함하는 Sirt6의 발현 촉진을 위한 시약 조성물을 제공한다.In addition, the present invention provides a reagent composition for promoting the expression of Sirt6 comprising 4-hexylresorcinol as an active ingredient.
이하, 본 발명의 이해를 돕기 위하여 실험예 및 실시예를 들어 상세하게 설명하기로 한다. 다만 하기의 실험예 및 실시예는 본 발명의 내용을 예시하는 것일 뿐 본 발명의 범위가 하기 실험예 및 실시예에 한정되는 것은 아니다. 본 발명의 실험예 및 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, experimental examples and examples will be described in detail to aid understanding of the present invention. However, the following experimental examples and examples are merely illustrative of the contents of the present invention, but the scope of the present invention is not limited to the following experimental examples and examples. Experimental examples and examples of the present invention are provided to more completely explain the present invention to those skilled in the art.
<실험예> 실험 재료 및 방법<Experimental Example> Experimental Materials and Methods
하기의 실험예들은 본 발명에 따른 각각의 실시예에 공통적으로 적용되는 실험예를 제공하기 위한 것이다.The following experimental examples are intended to provide experimental examples commonly applied to each embodiment according to the present invention.
1. 시약 및 기계1. Reagents and Machines
Fetal bovine serum (FBS)는 GIBCO (Grand Island, NY, U.S.A), oligo(dT)는 Promega (Madison, WI, USA)에서 구입하고, penicillin/streptomycin는 Lonza (Rockland, ME, USA)에서 구입하고, SuperScript Ⅱ Reverse Transcriptase는 Intron (iNtRON Biotechnology, Gyeinggi-do, Korea)에서 구입하고, SYBR green master mixture는 ABI (Carlsbad, CA, U.S.A)에서 구입하였다.Fetal bovine serum (FBS) was purchased from GIBCO (Grand Island, NY, USA), oligo(dT) was purchased from Promega (Madison, WI, USA), and penicillin/streptomycin was purchased from Lonza (Rockland, ME, USA). SuperScript Ⅱ Reverse Transcriptase was purchased from Intron (iNtRON Biotechnology, Gyeinggi-do, Korea), and SYBR green master mixture was purchased from ABI (Carlsbad, CA, USA).
Real-time PCR은 ViiA7 (Applied Biosystems, CA, U.S.A)을 사용하였고, DNA 및 RNA 정량은 Nano drop 2000, Incubator는 Thermo scientific(Rockford, IL, U.S.A)을 사용하였다. Protein 정량는 ELISA reader (TECAN, Mannedorf, Switzerland)를 사용하였다.ViiA7 (Applied Biosystems, CA, USA) was used for real-time PCR, Nano drop 2000 was used for DNA and RNA quantification, and Thermo scientific (Rockford, IL, USA) was used for incubator. Protein quantification was performed using an ELISA reader (TECAN, Mannedorf, Switzerland).
2. HUVEC 배양2. Culturing HUVECs
HUVECs (Lonza, Walkersville, MD, USA)를 구입하여 1 μg/mL 하이드로 코르티손(hydrocortison), 12 μg/mL 소 뇌 추출물 (bovine brain extract), 50 μg/mL 젠타마이신 (gentamicin), 50 ng/mL 암포테리신-B (amphotericin-B), 10 ng/mL 표피성장인자(EGF), VEGF, FGF-2, 헤파린, 아스코르브산 및 10% 우태아혈청 (EGMTM-2, Clonetics®, Lonza, Walkersville, MD, USA)을 포함하는 내피 세포 성장 배지 -2 (Clonetics®, Lonza)에서 배양하였다. 세포는 37.5℃, 5% CO2 인큐베이터에서 배양되었으며, 마이코플라스마가 없는 세포 만 분석되었는지 확인하기 위해 정기적으로 마이코플라스마 assay를 이용하여 검증하였다.HUVECs (Lonza, Walkersville, MD, USA) were purchased and supplemented with 1 μg/mL hydrocortison, 12 μg/mL bovine brain extract, 50 μg/mL gentamicin, and 50 ng/mL Amphotericin-B, 10 ng/mL epidermal growth factor (EGF), VEGF, FGF-2, heparin, ascorbic acid and 10% fetal bovine serum (EGMTM-2, Clonetics®, Lonza, Walkersville, MD, USA) containing endothelial cell growth medium-2 (Clonetics®, Lonza). The cells were cultured in an incubator at 37.5°C and 5% CO 2 , and were routinely verified using a mycoplasma assay to ensure that only mycoplasma-free cells were analyzed.
3. Real-time PCR3. Real-time PCR
Sirt6의 유전자 발현변화를 확인하기 위해 Real-time PCR을 수행하였다. 4-헥실레조르시놀(4-hexylresorcinol, 4-HR)을 농도별로 0, 1, 10, 100 μM씩 처리하고 24 시간 뒤 Total RNA를 추출하여, 1.5 ㎍의 Total RNA을 역전사효소를 이용하여 cDNA로 합성하였다. 합성된 cDNA 4 ㎕ (1/40 dilution)에 2× SYBR green PCR master mixture (5 ㎕)와 specific primer (0.5 ㎕)를 섞어서 real-time PCR을 수행하였다. Real-time PCR에 사용한 primer 세트(F: TGTGCCAAGTGTAAGACGCA, 서열번호 1; 및 R: CTTGGCCTTCACCCTTTTG, 서열번호 2)를 사용하였다.Real-time PCR was performed to confirm the gene expression change of Sirt6. 4-hexylresorcinol (4-HR) was treated with 0, 1, 10, and 100 μM for each concentration, and 24 hours later, total RNA was extracted and 1.5 μg of total RNA was converted into cDNA using reverse transcriptase. was synthesized with Real-time PCR was performed by mixing 2× SYBR green PCR master mixture (5 μl) and specific primer (0.5 μl) with 4 μl (1/40 dilution) of the synthesized cDNA. Primer sets used for real-time PCR (F: TGTGCCAAGTGTAAGACGCA, SEQ ID NO: 1; and R: CTTGGCCTTCACCCTTTTG, SEQ ID NO: 2) were used.
4. Western blot4. Western blot
Sirt 6의 단백질 발현변화를 확인하기 위해 HUVEC 세포수가 70%정도 일 때 4-HR을 0, 1, 10, 100 μM로 처리하여 2, 8, 24 시간 뒤에 단백질을 추출하였다. 단백질 정량을 하고 sirt 6 항체를 (Abcam, Cambridge, UK)로 western blot을 시행하여 sirt 6의 단백질 발현을 확인하였다.To confirm the protein expression change of
실시예: 4-HR이 Sirt6의 발현에 미치는 영향 평가Example: Evaluation of the effect of 4-HR on the expression of Sirt6
4-헥실레조르시놀(4-hexylresorcinol)이 항노화 및 수면연장 인자인 Sirt6 유전자의 발현에 미치는 영향을 평가하였다. 도 2 및 3에 나타난 바와 같이, 4-헥실레조르시놀(4-hexylresorcinol)이 인간 혈관내피세포(HUVECs)에서 Sirt6 유전자의 발현을 촉진할 뿐만 아니라, Sirtuin 6 단백질 발현을 촉진하는 것으로 확인되었다. 상기 결과는 항노화 및 건강한 수면연장과 관련된 Sirt6 유전자의 발현을 4-헥실레조르시놀(4-hexylresorcinol)이 촉진하는 것을 입증하며, 4-헥실레조르시놀(4-hexylresorcinol)이 항노화제로 사용될 수 있음을 입증한다.The effect of 4-hexylresorcinol on the expression of Sirt6 gene, an anti-aging and sleep prolonging factor, was evaluated. As shown in FIGS. 2 and 3 , it was confirmed that 4-hexylresorcinol promotes Sirt6 gene expression as well as
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 즉, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다.Having described specific parts of the present invention in detail above, it is clear to those skilled in the art that these specific descriptions are only preferred embodiments, and the scope of the present invention is not limited thereby. Do. That is, the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims (8)
A reagent composition for promoting the expression of Sirt6, comprising 4-hexylresorcinol as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210075500A KR102655961B1 (en) | 2021-06-10 | 2021-06-10 | Anti-aging composition comprising 4-hexylresorcinol as an active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210075500A KR102655961B1 (en) | 2021-06-10 | 2021-06-10 | Anti-aging composition comprising 4-hexylresorcinol as an active ingredient |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220166578A true KR20220166578A (en) | 2022-12-19 |
| KR102655961B1 KR102655961B1 (en) | 2024-04-11 |
Family
ID=84535320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210075500A KR102655961B1 (en) | 2021-06-10 | 2021-06-10 | Anti-aging composition comprising 4-hexylresorcinol as an active ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102655961B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110036686A (en) * | 2009-10-02 | 2011-04-08 | 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 | Compositions comprising a skin-lightening resorcinol and a skin darkening agent |
| KR101209129B1 (en) | 2010-09-02 | 2012-12-07 | 부산대학교 산학협력단 | Composition for proliferation, differentiation, and anti-aging of mesenchymal stem cell using miRNA control |
-
2021
- 2021-06-10 KR KR1020210075500A patent/KR102655961B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110036686A (en) * | 2009-10-02 | 2011-04-08 | 존슨 앤드 존슨 컨수머 캄파니즈, 인코포레이티드 | Compositions comprising a skin-lightening resorcinol and a skin darkening agent |
| KR101209129B1 (en) | 2010-09-02 | 2012-12-07 | 부산대학교 산학협력단 | Composition for proliferation, differentiation, and anti-aging of mesenchymal stem cell using miRNA control |
Non-Patent Citations (2)
| Title |
|---|
| Applied Sciences, Vol.11, No.8, pp.1-10 (2021.4.18.) 1부.* * |
| BioMed research international, Vol.2014, pp.1-13 (2014) 1부.* * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102655961B1 (en) | 2024-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Hypoxic preconditioning combined with curcumin promotes cell survival and mitochondrial quality of bone marrow mesenchymal stem cells, and accelerates cutaneous wound healing via PGC-1α/SIRT3/HIF-1α signaling | |
| KR100821683B1 (en) | A composition containing icariside ii for preventing and treating diseases associated with abnormal angiogenesis | |
| CN111356468B (en) | Composition for preventing or treating fibrotic diseases comprising Rhus succedanea extract as active ingredient | |
| KR102459434B1 (en) | Composition for improvment, prevention or treatment in muscular atrophy comprising extracts of Potentilla chinensis or Indigo | |
| KR102309911B1 (en) | Discovery of novel Akkermansia muciniphila AK32 strain and application for preventing or treating intestinal injury | |
| KR102655961B1 (en) | Anti-aging composition comprising 4-hexylresorcinol as an active ingredient | |
| KR102246097B1 (en) | Pharmaceutical composition for treating ototoxicity hearing loss by additional effect of cisplatin comprising alpha-lipoic acid | |
| KR101810256B1 (en) | Anti-androgenic agent, sebum secretion blocker, hair growth stimulant, and food or beverage | |
| KR20180027095A (en) | Enzyme treated Mugunghwa extracts for improving skin wrinkle | |
| KR102187865B1 (en) | Composition for inhibiting stemness of stem cell comprising material for inhibiting methylation of OCT4 | |
| KR101554343B1 (en) | Pharmaceutical compositions for the prevention and treatment of the neuro-degenerative Disorders | |
| Shati | Xanthohumol protects against renal ischaemia reperfusion (I/R) injury by scavenging ROS and inhibition of JAK-2/STAT-3 inflammatory pathway | |
| KR101605343B1 (en) | Composition for Anticancer or Antioxidant Containing Quamoclit Extract or Novel Compound Isolated from Quamoclit | |
| KR100467471B1 (en) | Pharmaceutical preparations containing cultured basidiocarps of Phellinus linteus extract for prevention and treatment of neurodegenerative disease | |
| KR101658515B1 (en) | A composition comprising extract of Platycodon grandiflorum or saponin compounds isolated therefrom for preventing vascular aging | |
| KR20190088758A (en) | Anti-atopic composition comprising extract of Geomgangsong thinning by-product as effective component | |
| KR102366476B1 (en) | Composition comprising Erigeron annuus (L.) Pers. for preventing or treating of Degenerative Brain Diseases | |
| KR101094733B1 (en) | Composition for improving adultdisease or anti-aging comprising natokinase and royal jelly | |
| KR102618160B1 (en) | A composition comprising the extract of Nephelium lappaceum seed or flavonoids isolated therefrom as an active ingredient of a senomorphic agent for inhibiting aging-related symptoms and for preventing and treating senescence-associated diseases | |
| KR102015448B1 (en) | An anti-inflamatory composition comprising extract of Celtis choseniana as an active ingredient | |
| KR102095749B1 (en) | Composition for prevention or treatment of a disease occured by autophagy disorder in mitochondria comprising expression inhibitors of S6K1 gene or activity inhibitors of S6K1 protein | |
| KR20120057125A (en) | Pharmaceutical composition for preventing or treating hepatocellular carcinoma containing ginsenoside Rd as effective components | |
| KR20230092191A (en) | COMPOSITION FOR PREVENTION OR TREATMENT OF MUSCLE WEAKNESS DISEASE OR SARCOPENIA COMPRISING Berchemia berchemiifolia (Makino) Koidz. EXTRACT AS AN EFFECTIVE INGREDIENT | |
| KR20230134813A (en) | Pharmaceutical composition for preventing or treating nasal polyps comprising streptomyces sp. SNC087 or staurosporine isolated therefrom as an active ingredient | |
| KR20170025801A (en) | Composition for preventing or treating skin photoaging comprising Pueraria lobata root extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |